# Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer

> **NCT02386397** · PHASE1,PHASE2 · COMPLETED · sponsor: **Institut du Cancer de Montpellier - Val d'Aurelle** · enrollment: 66 (actual)

## Conditions studied

- Digestive Cancer

## Interventions

- **DRUG:** Regorafenib
- **DRUG:** GEMOX

## Key facts

- **NCT ID:** NCT02386397
- **Lead sponsor:** Institut du Cancer de Montpellier - Val d'Aurelle
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-09
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 66 (ACTUAL)
- **Last updated:** 2026-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02386397

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02386397, "Activity of Regorafenib in Combination With Chemotherapy in Patients With Advanced Biliary Tract Cancer". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02386397. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*